Abstract Accepted for Oral Presentation at EANM on DETECT Study Evaluating ⁹⁹ᵐTc-Maraciclatide as a New Imaging Marker for Endometriosis

London, UK, 9 July 2024. Serac Healthcare Limited (“Serac Healthcare” or “the Company”), a clinical radiopharmaceutical company developing an innovative molecular imaging agent, announces that an abstract on preliminary data from the DETECT “Detecting Endometriosis expressed integrins using technetium-99m” imaging study, has been accepted for oral presentation at the annual congress of the European Association of Nuclear Medicine (EANM) taking place from 18-23 October 2024 in Hamburg, Germany.

Share this article with a friend

Create an account to access this functionality.
Discover the advantages